Family · Pharmaceutical analytical standards
Relugolix
A GnRH receptor antagonist taken as a tablet: it blocks the signal by which the pituitary gland stimulates the production of testosterone and oestrogens. Approved in Japan in 2019 for uterine fibroids and in the United States in 2020 for advanced prostate cancer. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Unlike GnRH analogues, modified copies of the natural hormone that are usually given by injection, relugolix is a small non-peptide molecule: that is why it can be taken by mouth.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
